Newsfeeds - Spark Newswire

1 minute read

Daré Bioscience Announces Pharmacokinetic Results From DARE-HRT1 Phase 1 / 2 Study That Support Potential Pf DARE-HRT1 As Hormone Therapy For Both Vasomotor And Vaginal Symptoms of Menopause

Today, 5:09 PM

Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal

DARE

2 minute read

Analyst Ratings

HC Wainwright & Co. Maintains Buy Rating for Dare Bioscience: Here’s What You Need To Know

By Benzinga Insights

Today, 5:09 PM

HC Wainwright & Co. has decided to maintain its Buy rating of Dare Bioscience (NASDAQ:DARE) and raise its…

DARE

15 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For December 1, 2022

By Benzinga Insights

Today, 5:09 PM

Upgrades Northcoast Research upgraded the previous rating for SpartanNash Co (NASDAQ:SPTN) from Neutral to Buy. SpartanNash earned $0.55…

ACRS

1 minute read

JonesTrading Initiates Coverage On Dare Bioscience with Buy Rating, Announces Price Target of $6

By Benzinga Newsdesk

Today, 5:09 PM

JonesTrading analyst Catherine Novack initiates coverage on Dare Bioscience (NASDAQ:DARE) with a Buy rating and announces Price Target of $6.

DARE

1 minute read

Dare Bioscience Q3 EPS $(0.08) Beats $(0.12) Estimate. Cash And Cash Equivalents Of $40.4M

By Benzinga Newsdesk

Today, 5:09 PM

Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 33.33 percent. This is a 55.56 percent increase over losses of $(0.18) per share from

DARE

1 minute read

News

President Biden To Push Abortion-Rights Bill If Democrats Keep Control Of Congress

By Benzinga Newsdesk

Today, 5:09 PM

- Dow Jones Citing Wall Street Journal

AGRX

1 minute read

Daré Bioscience’s Intravaginal Ring Improves Vasomotor, Vaginal Symptoms Of Menopause

By Vandana Singh

Today, 5:09 PM

Daré Bioscience Inc (NASDAQ:DARE) announced topline efficacy results from its Phase 1/2 trial of DARE-HRT1. DARE-HRT1 is a novel, investigational intravaginal…

DARE

1 minute read

Daré Bioscience Announces Efficacy Results From The DARE-HRT1 Phase 1 / 2 Study

By Benzinga Newsdesk

Today, 5:09 PM

Statistically Significant Results for Improvement in both the Vasomotor and the Vaginal Symptoms of Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both

DARE

30 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 5:09 PM

During Wednesday's trading, 517 companies set new 52-week lows.

$APE

3 minute read

Daré Bioscience Announces IDE Approval For A Single Arm, Open-Label Pivotal Contraceptive Efficacy Study Of Ovaprene, An Investigational Hormone-Free Monthly Intravaginal Contraceptive

By Benzinga Newsdesk

Today, 5:09 PM

Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that the U.S. Food & Drug Administration (FDA) approved an Investigational Device Exemption (IDE) application

DARE